Clinical Trials Browser

Uveal Melanoma

Uveal Melanoma, Melanoma

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

Brain Neoplasms, Melanoma

Melanoma, Skin Neoplasms

Breast Neoplasms, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms

Melanoma, Neoplasm Metastasis, Skin Neoplasms

Uveal Melanoma

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

Melanoma, Neoplasms, Skin Neoplasms

Melanoma, Skin Neoplasms

Melanoma, Neoplasm Metastasis

Uveal Melanoma, Melanoma

Uveal Melanoma, Melanoma

Uveal Melanoma, Melanoma

Brain Neoplasms, Melanoma

Glioblastoma, Melanoma

Melanoma, Neoplasm Metastasis

Clinical Trials

Ipilimumab + Temozolomide in Metastatic Melanoma

Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients

Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

KEYNOTE 002

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma

High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma

Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients

A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

UPCI-07-008

Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)

Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)

Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection

Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma

Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma

BBI

Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma

Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma

Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma

BCAA

S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)

Taxotere/Temodar/Cisplatin Study in Melanoma Patients

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

MEL0107

Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma